Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy boosts radiation against early lung cancer

NCT ID NCT03148327

Terminated Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study investigates whether adding the immunotherapy drug durvalumab to stereotactic body radiation therapy (SABR) improves outcomes for people with early-stage non-small cell lung cancer who cannot have surgery. Participants are randomly assigned to receive either SABR alone or SABR plus durvalumab. The trial aims to assess safety, tumor control, and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
durvalumab (an immunotherapy drug) combined with stereotactic body radiation therapy (SABR)
What this could lead to
If successful, this combination could improve tumor control and extend survival for people with early-stage lung cancer who cannot undergo surgery.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. Adding immunotherapy to radiation may increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

  • Jonsson Comprehensieve Cancer Center

    Los Angeles, California, 90095, United States

  • New York Weill Cornell Cancer Center at Cornell University

    New York, New York, 10021, United States

  • Peter MacCallum Cancer Centre

    Melbourne E., Victoria, 3000, Australia

  • University of Colorado

    Denver, Colorado, 80217-3364, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.